about
Acid sphingomyelinase–ceramide system mediates effects of antidepressant drugsPrimary amyloidoma of the brain parenchyma.Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples.Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomographyCilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.The management of lomustine overdose in malignant glioma patients.CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cellsModulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transitionComplete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trialVertebral artery dissection presenting with ispilateral acute C5 and C6 sensorimotor radiculopathy: A case report.Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.Primetime for antiangiogenic therapy.Targeting integrins in malignant glioma.Molecular diagnostics of gliomas: the clinical perspective.Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?Glioblastoma stem cells.Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach?The role of integrins in glioma biology and anti-glioma therapies.Clinical implications of molecular neuropathology and biomarkers for malignant glioma.Malignant astrocytoma in elderly patients: where do we stand?Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma.The role of integrins in primary and secondary brain tumors.Differential regulation of TGF-β-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastomaTargeting the bHLH transcriptional networks by mutated E proteins in experimental glioma.Integrin control of the transforming growth factor-β pathway in glioblastoma.HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells.GDF-15 contributes to proliferation and immune escape of malignant gliomas.Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma.VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells.Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL.Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.Wnt signalling inhibits neural differentiation of embryonic stem cells by controlling bone morphogenetic protein expression.Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.Proceedings of the WFNS Neuro-Oncology Committee Workshop Rome 2015.ATRX immunostaining predicts IDH and H3F3A status in gliomas.[Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
P50
Q29042551-DDACD5F4-AB38-4838-9DB7-68FD9FA0E784Q30984827-26B8C39F-BE6F-4EF6-92B3-6700FD2EAC7CQ33262451-3D4BD2FB-9E19-4494-B8A8-2204320D8609Q33401179-BCF2DEE4-0F02-447D-B779-D0C6911D9D2AQ34148786-F617156A-E690-43FD-A820-C5551DB7B1BDQ34398926-C53AD6F3-FA12-420A-B059-7E286133774AQ34718233-E2CF5282-229D-4AD3-A5FB-D911B4BE63F4Q34722539-EE647A12-6AA9-4290-B469-82B0CABBAA64Q35206271-CF8072D3-B519-4975-BF2F-8898B411D2DFQ35422357-283D5DAB-2BC1-4A46-B201-4D4841BE5134Q36355997-4D67E267-B772-44E2-A144-B241524E3DC8Q36705933-F356B9B8-A7F1-485F-A058-57FFFCBCDA67Q36881947-8DC5E5AD-1BFB-42B5-9530-D8B73A0734C0Q37231972-B6B457D6-F3CF-461A-B1B2-EEF1E4A090F5Q37604842-974F78BA-5296-4FA7-A89D-48E0171F5C76Q37785812-C6E76E5A-251E-4271-9A73-DF060856B125Q37791463-96335B7B-5EA3-4C6F-9C89-570C8AE3E663Q37797464-C45181B5-4C21-4B15-B071-DA6BFCC08428Q37831190-2DE495CD-E683-4CDE-ACFF-3E68878CE6FEQ37895369-C8B51847-38E6-4EB2-9F58-9224EA74A6F3Q37914246-EB1079FE-5D00-47D4-877E-13D85C82D1D1Q37994631-755536BB-A8FB-4EFE-BCC5-FA3435743094Q38155009-6018AD83-D3D6-458D-A25E-28D644E6F321Q38439110-3D1FE024-D8C7-42B8-BC8E-6FB6816DE17FQ38813049-1FE8E431-FA03-4CA4-9821-E52CEA82D7A4Q38962204-2DA50BAC-2FD9-4B19-8466-F11551D9E122Q38981263-756B8145-6996-473D-A247-7643CB9D911EQ39200138-04E6E87E-6E2A-41F3-B23C-2DC08E038710Q39333069-2572AC16-E9E7-4528-9838-B0EDABB6DADDQ39695192-B4E58680-CFD8-497C-8285-D906CB3C268FQ39766941-4A92DF38-1106-4148-B381-BBC830E2EF85Q39952546-396579D2-759C-4227-B1BD-E77042F45640Q39956664-3902F863-E328-41B1-ACB9-6D478D72408DQ40256595-3AB662BE-372E-4356-808B-C8C65ADBD844Q40609090-CBBE647B-003F-4C42-B3FD-B4CA8183AABCQ42168743-657DFD4C-F14D-4193-A6F9-4CC5A22BCE7DQ42323457-D66BB079-01DB-48AC-93F9-E41E6313D8EEQ42701263-B573587C-B401-42D7-9BC5-AF042D4B5772Q42952924-A70AF2A7-F160-4688-9186-97EFB0F8B1B3Q45324493-A52D4126-9C53-433C-901D-85448E8CD469
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ghazaleh Tabatabai
@ast
Ghazaleh Tabatabai
@en
Ghazaleh Tabatabai
@es
Ghazaleh Tabatabai
@nl
Ghazaleh Tabatabai
@sl
type
label
Ghazaleh Tabatabai
@ast
Ghazaleh Tabatabai
@en
Ghazaleh Tabatabai
@es
Ghazaleh Tabatabai
@nl
Ghazaleh Tabatabai
@sl
prefLabel
Ghazaleh Tabatabai
@ast
Ghazaleh Tabatabai
@en
Ghazaleh Tabatabai
@es
Ghazaleh Tabatabai
@nl
Ghazaleh Tabatabai
@sl
P214
P1053
A-6365-2015
P106
P213
0000 0000 1325 2208
P214
P31
P3829
P496
0000-0003-3702-923X
P7859
viaf-10787920